ダウンロード数 : ?
ファイル
言語
英語
著者
Katagiri, Hiroshi 1Department of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo, Shimane 6938501
Sultana, Razia 1Department of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo, Shimane 6938501
Sanuki, Kaori 1Department of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo, Shimane 6938501
Nakayama, Satoru Departments of Obstetrics and Gynecology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka 4308558
Otsuki, Yoshiro Departments of Pathology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka 4308558
Ishikawa, Noriyuki Department of Organ Pathology, Shimane University School of Medicine, Izumo, Shimane 6938501
内容記述(抄録等)
The clinicopathological significance and prognostic value of the expression of proteins associated with autophagy, beclin 1 (BECN1), 1A/1B‑light chain 3 (LC3) and high mobility group box‑1 protein (HMGB‑1), were investigated in patients with ovarian carcinoma, receiving combination chemotherapy with a platinum agent and a taxane. Immunohistochemical staining was performed for autophagy‑associated proteins in tumor tissues from 141 patients with ovarian carcinoma. Clinical data were collected retrospectively by reviewing medical charts, and the association between protein expression, clinicopathological features and survival was investigated. Amongst 141 ovarian carcinoma samples, the loss of BECN1, LC3, and HMGB‑1 expression was identified in 59 (41.8%), 35 (24.8%), and 66 (46.8%) samples, respectively. Clinicopathological factors were not significantly associated with the loss of BECN1 expression. However, significant associations were demonstrated between the expression of BECN1, LC3, and HMGB‑1. In addition, loss of BECN1 expression demonstrated a significant association with poor progression‑free and poor overall survival. Multivariate analysis demonstrated that loss of BECN1 expression and postoperative residual tumor were significant independent predictors of poor progression‑free survival and poor overall survival. These results indicated that loss of BECN1 expression in ovarian carcinoma is a negative prognosticator in patients receiving platinum‑based chemotherapy. Assessment of BECN1 expression may be useful for predicting an unfavorable response to platinum‑based chemotherapy in ovarian carcinoma.
主題
ovarian carcinoma
beclin 1
survival
platinum
taxane
掲載誌名
Oncology Letters
15
1
開始ページ
1170
終了ページ
1176
ISSN
1792-1074
ISSN(Online)
1792-1082
発行日
2017-11-9
DOI
出版者
Spandidos Publications
資料タイプ
学術雑誌論文
ファイル形式
PDF
著者版/出版社版
出版社版
業績ID
e36787
部局
医学部